Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659363 | 1.00 | FFAR1 (0.43) | FFAR1METUSP30 | |
| SCHEMBL2030744 | 0.89 | FFAR1 (0.44) | FFAR1MET | |
| SCHEMBL1987497 | 0.85 | FFAR1 (0.49) | FFAR1USP30 | |
| SCHEMBL22900932 | 0.84 | FFAR1 (0.42) | FFAR1 | |
| SCHEMBL26911769 | 0.82 | FFAR1 (0.43) | FFAR1 | |
| SCHEMBL26911766 | 0.82 | FFAR1 (0.43) | FFAR1 | |
| SCHEMBL29273536 | 0.80 | FFAR1 (0.45) | FFAR1 | |
| SCHEMBL2517121 | 0.80 | FFAR1 (0.47) | FFAR1 | |
| SCHEMBL2572488 | 0.80 | FFAR1 (0.47) | FFAR1 | |
| SCHEMBL27324144 | 0.79 | FFAR1 (0.47) | FFAR1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552804-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| US-12441731-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2025-02-20 | — | — | US | disclosed |
| US-20240309008-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-09-19 | — | — | US | disclosed |
| US-12083124-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240287086-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2024-08-29 | — | — | US | disclosed |
| US-12030889-B2 | Imidazopyridazine and imidazopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12012409-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-06-18 | — | — | US | disclosed |
| US-11897891-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-02-13 | — | — | US | disclosed |
| EP-3856348-B1 | PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 AND/OR FGFR MODULATORS | INCYTE CORP (US) | 2024-01-03 | — | — | EP | disclosed |
| US-9096624-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140088114-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals ,LLC | 2014-03-27 | — | — | US | disclosed |
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130072495-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC | 2013-03-21 | — | — | US | disclosed |
| US-8399433-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2438056-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2010141406-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012409-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR3, FGFR2, FGFR1 | FFAR1 1461/4885MET 36/4885USP30 4251/4885 |
| US-12083124-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | FFAR1 1114/4885MET 32/4885USP30 4294/4885 |
| US-11897891-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | FFAR1 1699/4885MET 31/4885USP30 3898/4885 |
| US-12441731-B2 | Pyrazolopyrimidine compounds and uses thereof | ALK, FGFR1, FGFR2 | FFAR1 1535/4885MET 64/4885USP30 4723/4885 |
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | FFAR1 1703/4885MET 585/4885USP30 4486/4885 |
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | FFAR1 1114/4885MET 32/4885USP30 4294/4885 |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | FFAR1 2193/4885MET 1182/4885USP30 2453/4885 |
| US-20130072495-A1 | FUSED BICYCLIC KINASE INHIBITORS | IGF1R, MET, ALK | FFAR1 167/4885MET 2/4885USP30 3713/4885 |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | FFAR1 1703/4885MET 585/4885USP30 4486/4885 |
| US-20240287086-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | FFAR1 1699/4885MET 31/4885USP30 3898/4885 |
| US-12030889-B2 | Imidazopyridazine and imidazopyridine compounds and uses thereof | ALK, ABL2, ACVR2A | FFAR1 2622/4885MET 714/4885USP30 4365/4885 |
| US-12552804-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | FFAR1 1016/4885MET 13/4885USP30 4112/4885 |
| US-20140088114-A1 | FUSED BICYCLIC KINASE INHIBITORS | IGF1R, MET, RET | FFAR1 148/4885MET 2/4885USP30 4160/4885 |
| US-20240309008-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | ALK, ABL2, ACVR2A | FFAR1 2622/4885MET 714/4885USP30 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.